Benefits
Liver Health and Hepatoprotection
Siliphos provides bioavailable silybin for liver protection — multiple clinical trials in liver applications including fatty liver, viral hepatitis adjunct, and hepatotoxic exposure protection.
Fatty Liver (NAFLD) Support
Multiple trials show Siliphos improves liver enzyme markers (ALT, AST) and steatosis markers in non-alcoholic fatty liver disease.
10× Bioavailability vs Standard Silymarin
Standard silymarin (containing silybin + other flavonolignans) has poor bioavailability; Siliphos addresses this. Critical for clinical efficacy.
Antioxidant Liver Cell Protection
Silybin protects hepatocytes from oxidative damage; supports glutathione regeneration; foundation of liver protective effects.
Hepatotoxic Exposure Adjunct
Used as adjunct for hepatotoxic medications, alcohol-related liver stress, environmental toxin exposure.
Mechanism of action
Silybin Most Active Component
Silymarin from milk thistle is mixture of flavonolignans — silybin (silibinin) is the most active component; comprises ~50-60% of silymarin. Siliphos focuses on silybin specifically for higher activity.
Phytosome® Bioavailability Enhancement
Standard silymarin has poor bioavailability (~5-10%); Phytosome improves silybin absorption ~10×.
Hepatocyte Membrane Protection
Silybin stabilizes hepatocyte (liver cell) membranes; protects from toxin entry; foundation of antidote effect against amanita mushroom poisoning.
Antioxidant and Glutathione Support
Direct antioxidant + supports endogenous glutathione (master liver antioxidant) regeneration.
Anti-Inflammatory Liver Effects
Reduces inflammatory markers in liver tissue.
Clinical trials
Multiple Siliphos trials in NAFLD patients on liver enzymes, steatosis, fibrosis markers.
NAFLD patients.
The main randomized trial (RealSIL) tested silybin combined with phosphatidylcholine and vitamin E and showed improvements in ALT, AST, and steatosis markers vs placebo; benefits for the silybin-phospholipid complex alone are extrapolated from this combination.
Pooled analyses of silymarin (including bioavailable forms like Siliphos) for various liver conditions.
Various liver disease populations.
Evidence is mixed overall: several trials and pooled analyses show liver-enzyme improvements, while systematic reviews (including Cochrane) have found milk thistle does not clearly reduce mortality or major complications in liver disease. Bioavailable forms like Siliphos absorb more consistently, but overall efficacy remains moderate.